Age-Related Macular Degeneration Clinical Trials

Recruiting Age-Related Macular Degeneration studies

• A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
  NCT07614776PHASE3AmgenFullerton, California
• Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
  NCT07007065PHASE3AbbVieMesa, Arizona
• Extension Study for the Port Delivery System With Ranibizumab (Portal)
  NCT03683251PHASE3Hoffmann-La RochePhoenix, Arizona
• A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
  NCT06541704PHASE3Regeneron PharmaceuticalsChandler, Arizona
• Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
  NCT06990269PHASE2ADARx Pharmaceuticals, Inc.Gilbert, Arizona
• A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
  NCT07440225PHASE2, PHASE3EyeBiotech Ltd.Scottsdale, Arizona
• A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
  NCT07496567PHASE2, PHASE3EyeBiotech Ltd.Gilbert, Arizona
• Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot Study
  NCT07556406University of California, San FranciscoSan Francisco, California
• A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
  NCT07215390PHASE2Apellis Pharmaceuticals, Inc.Gilbert, Arizona
• A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
  NCT04853251PHASE4Genentech, Inc.Mesa, Arizona
• A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD
  NCT07158775PHASE1, PHASE2Bionic Sight LLCEdison, New Jersey
• Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
  NCT05407636PHASE3AbbViePhoenix, Arizona

See all 53 recruiting Age-Related Macular Degeneration trials →

Age-Related Macular Degeneration trials by state

• California
• Texas
• New York
• Florida
• Pennsylvania
• Massachusetts
• Ohio
• Illinois
• North Carolina
• Maryland
• Georgia
• Tennessee

Age-Related Macular Degeneration trials by metro

• New York
• Houston
• Boston
• Chicago
• Philadelphia
• Los Angeles
• Dallas
• Atlanta
• Miami
• Nashville
• Rochester
• Baltimore

Frequently asked questions

How do I find recruiting Age-Related Macular Degeneration clinical trials?

Corterve aggregates actively recruiting Age-Related Macular Degeneration studies from the public ClinicalTrials.gov registry. Browse the studies listed on this page or take a free health assessment to see trials you may qualify for based on your profile.

Are Age-Related Macular Degeneration clinical trials free to join?

Study participation is typically free — research sponsors cover the cost of the investigational treatment and study-related visits. Many trials also compensate participants for time and travel. Details vary by study.

Who can take part in a Age-Related Macular Degeneration clinical trial?

Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.